Patient-reported resilience associated with outcomes after HCT

Share this content:

the ONA take:

Among long-term survivors of hematopoetic celltransplantation (HCT), patient-reported resilience is independently associated with health and psychosocial outcomes, according to a recent study published online ahead of print in Cancer.

Researchers led by Abby Rosenberg, MD, MS, of the Seattle Children’s Hospital observed 4,643 adult survivors of HCT as part of the annual Fred Hutchinson Cancer Research Center (FHCRC) post-transplant survivorship survey from July 2013 to June 2014.

The survey included patient-reported health and functional status as well as instruments that assessed psychosocial outcomes such as the 10-item Connor-Davidson Resilience scale, the Posttraumatic Growth Inventory, and the Cancer and Treatment Distress measure. Among those patients, 1,823 (39%) responded after a single mailing and subsequent reminder letter. Median age was 59 years and 52.5% of patients were male.

The researchers found that lower patient-reported resilience was associated with chronic graft-versus-host disease of higher severity, lower performance scores, missing work for health reasons, and permanent disability.

Upon adjusting for demographic and health characteristics, lower patient-reported resilience scores showed higher odds of having psychological distress as well as being in the lowest quartile for mental health-related quality of life.

“Future studies must determine whether interventions can bolster resilience and improve survivorship outcomes,” the authors concluded.

Shorter course of radiation for breast cancer offers patients an important benefit
Among long-term survivors of hematopoetic cell transplantation (HCT), patient-reported resilience is independently associated with outcomes.
Low patient-reported resilience is associated with an ongoing risk of poor health and psychosocial outcomes. Using a large cross-sectional sample of survivors of HSCT, this study explored associations between patient-reported resilience, psychological distress, posttraumatic growth, and HRQoL.
READ FULL ARTICLE From Wiley Online Library
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs